Characteristics of patients on day 1 of receiving baricitinib
| Characteristics | Patients Baricitinib (n=43) |
| Age, n | |
| <40 years | 3 (7%) |
| 40–59 years | 11 (26%) |
| 60–79 years | 19 (44%) |
| ≥80 years | 10 (23%) |
| Male gender, n | 30 (70%) |
| Comorbidities, n | |
| Dyslipidaemia | 19 (44%) |
| Hypertension | 22 (51%) |
| Heart disease | 12 (28%) |
| Diabetes | 11 (26%) |
| Respiratory disease | 6 (14%) |
| Chronic renal insufficiency | 2 (5%) |
| Cancer | 1 (2%) |
| Days of treatment with baricitinib, median (IQR) | 6 (5–7) |
| Initial 8-category ordinal scale, median (range)* | 6 (6–4) |
| 6. Hospitalised, receiving non-invasive ventilation or high-flow oxygen devices | 23 (53%) |
| 5. Hospitalised, requiring supplemental oxygen | 12 (28%) |
| 4. Hospitalised, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19-related or otherwise) | 8 (19%) |
| 3. Hospitalised, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalisation was extended for infection control reasons) | 0 (0%) |
| 2. Not hospitalised, limitation of activities, home oxygen requirement, or both | 0 (0%) |
| 1. Not hospitalised, no limitations of activities | 0 (0%) |
| Laboratory tests, median (IQR)† | |
| Serum creatinine (mg/dL; normal range 0.5–1.3) | 0.9 (0.74–1.04) |
| ≥1.3 | 4/43 (9%) |
| <1.3 | 39/43 (91%) |
| Interleukin (IL)-6 (pg/mL; normal range 0–0.7) | 53.0 (37.1–100.3) |
| ≥7.0 | 34/39 (87%) |
| <7.0 | 5/39 (13%) |
| C-reactive protein (mg/dL; normal range 0–5.0) | 89.8 (36.0–149.6) |
| ≥5.0 | 39/43 (91%) |
| <5.0 | 4/43 (9%) |
| Serum ferritin (ng/mL; normal range 21.0–275.0) | 716.0 (334.3–1261.8) |
| ≥275.0 | 22/28 (79%) |
| <275.0 | 6/28 (21%) |
| Lymphocyte count (×10 L; normal range 1.1–3.2) | 1.09 (0.82–1.51) |
| ≥1.1 | 21/43 (49%) |
| <1.1 | 22/43 (51%) |
| Platelets (×109/L; normal range 100.0–350.0) | 266.0 (217.0–336.0) |
| ≥100 | 43/43 (100%) |
| <100 | 0/43 (0%) |
| D-dimer (µg/L; normal range 0.0–1.5) | 9.56 (4.5–16.9) |
| ≥1.5 | 42/43 (98%) |
| <1.5 | 1/43 (2%) |
| Medication during admission, n | |
| Azithromycin | 42 (98%) |
| Ceftriaxone | 36 (84%) |
| Other antibiotic agent | 19 (44%) |
| Chloroquine or hydroxychloroquine | 42 (98%) |
| Low molecular weight heparins (LMWH) | 37 (86%) |
| Corticosteroids | 36 (84%) |
| Tocilizumab | 8 (19%) |
| Convalescent plasma | 2 (5%) |
| Lopinavir/ritonavir | 9 (21%) |
| Darunavir/cobicistat | 1 (2%) |
| Famciclovir | 1 (2%) |
| Colchicine | 1 (2%) |
Data are median (IQR), median (range), n (%) or n/N (%).
*Eight-category ordinal scale defined as follows: 1, not hospitalised, no limitations of activities; 2, not hospitalised, limitation of activities, home oxygen requirement, or both; 3, hospitalised, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalisation was extended for infection control reasons); 4, hospitalised, not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or other medical conditions); 5, hospitalised, requiring any supplemental oxygen; 6, hospitalised, requiring non-invasive ventilation or use of high-flow oxygen devices; 7, hospitalised, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation; and 8, death. It was measured on day 1 of administration of baricitinib.
†Initial laboratory tests were measured as the closest value to day 1 of baricitinib with a margin of 96 hours prior.